Archive for March, 2015

MWV95 - The Power of Fungal Genetics
ASMCultures magazine traveled to Colombia to speak with and film the researchers behind an innovative biotechnology project that is producing exciting results. The international Swiss ...

By: American Society for Microbiology

Continue reading here:
MWV95 - The Power of Fungal Genetics - Video

The Sims 3 - Perfect Genetics Challenge - Pt12 - Daddys Girl
If you like this video please leave a thumbs up, it really helps Open fully for *NEW SCHEDULE* info and social media links Weekly Schedule (Subject to change) Monday - Disney...

By: xSimSugar

The rest is here:
The Sims 3 - Perfect Genetics Challenge - Pt12 - Daddys Girl - Video

The ACMG Foundation for Genetic and Genomic Medicine announces the first recipient of the ACMG Foundation/David L. Rimoin Inspiring Excellence Award at the 2015 ACMG Annual Clinical Genetics Meeting in Salt Lake City, Utah

The ACMG Foundation for Genetic and Genomic Medicine is proud to announce that Marcus Miller, PhD of Baylor is the recipient of the inaugural ACMG Foundation/David L. Rimoin Inspiring Excellence Award. The Award was presented during the 2015 ACMG Annual Clinical Genetics Meeting in Salt Lake City, Utah.

The David L. Rimoin Inspiring Excellence Award was created in memory of the late Dr. David L Rimoin, one of the founders of ACMG who passed away in 2012. Dr. Rimoin touched the lives of generations of patients as well as trainees and colleagues. This award is a cash award given to a selected student, trainee, or junior faculty ACMG member whose abstract submission is chosen as a platform presentation during the ACMG Annual Clinical Genetics Meeting and complements the David L. Rimoin Lifetime Achievement Award, which will begin at the 2016 ACMG Annual Clinical Genetics Meeting in Tampa, Florida. Dr. Miller was selected to receive this award for his platform presentation, "Metabolomic Analysis Uncovers Significant Trimethylamine N-oxide Production in Patients with Inborn Errors of Metabolism Requiring Supplemental Carnitine Despite Dietary Meat Restrictions."

Dr. Miller completed his PhD in Genetics at the University of Wisconsin, Madison and his BS in Biology at Purdue University. He is currently a molecular genetics laboratory fellow at Baylor College of Medicine, he is working on research topics that include Metabolomic analysis using high precision mass spectrometry, approaches to metabolomic data analysis, molecular genetics of VLCAD deficiency especially as it relates to newborn screening, next generation sequencing, mitochondrial disorders, approaches to molecular genetic testing, and general human genetic disorders.

"The ACMG and ACMG Foundation for Genetic and Genomic Medicine would not be where it is today without the hard work of Dr. Rimoin, who was our founding president. This award will help keep his legacy alive in students, trainees and junior faculty ACMG members" said Bruce R. Korf, MD, PhD FACMG, president of the ACMG Foundation for Genetic and Genomic Medicine.

Ann Garber, Dr. Rimoin's widow said, "The Rimoin family is excited that Dr. Miller's outstanding work will be recognized and supported through the David L. Rimoin Inspiring Excellence Award. It would make David happy that the individualized therapeutic approaches advocated by Dr. Miller's findings are being brought to the forefront, as this was a major emphasis of his work and passion."

###

The ACMG Foundation for Genetic and Genomic Medicine, a 501(c)(3) nonprofit organization, is a community of supporters and contributors who understand the importance of medical genetics in healthcare. Established in 1992, the ACMG Foundation for Genetic and Genomic Medicine supports the American College of Medical Genetics and Genomics; mission to "translate genes into health" by raising funds to attract the next generation of medical geneticists and genetic counselors, to sponsor important research, to promote information about medical genetics, and much more.

To learn more about the important mission and projects of the ACMG Foundation for Genetic and Genomic Medicine and how you too can support this great cause, please visit http://www.acmgfoundation.org or contact us at acmgf@acmgfoundation.org or 301/718-2014.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

Follow this link:
Marcus Miller, Ph.D., receives ACMG Foundation/David L. Rimoin Inspiring Excellence Award

Combined gene/cell therapies provide long-term and pervasive rescue of multiple pathological...
Combined gene/cell therapies provide long-term and pervasive rescue of multiple pathological symptoms in a murine model of globoid cell leukodystrophy. Alessandra Ricca et al (2015), Human...

By: KeSimpulan

Excerpt from:
Combined gene/cell therapies provide long-term and pervasive rescue of multiple pathological... - Video

DNA GENE THERAPY
Vision restored to patient with DNA GENE THERAPY.

By: sunita agarwal

Read more here:
DNA GENE THERAPY - Video

GENE THERAPY FOR GENETIC EYE DISORDERS
FROM HAND MOVEMENT TO 6/60 VISION WITH #GENETHERAPY #DRAGARWALHOSPITALS #BANGALORE #DRSUNITAAGARWAL #INDIA #MEDICALTOURISM.

By: Sunithanahar

Go here to read the rest:
GENE THERAPY FOR GENETIC EYE DISORDERS - Video

Imagine if instead of using drugs or surgery, a doctor could simply insert a gene into a patient's cell to treat or prevent disease.

Gene therapy is endeavoring to do just that and could emerge in the coming years as a viable alternative for treatment. Certain conditions that previously couldn't be treated, such as forms of blindness, types of cancer or more rare conditions like sickle cell disease are now being researched with this alternative treatment.

Phil Nadeau, biotechnology analyst with Cowen and Company, predicts there will be several gene therapy products approved by the F.D.A. within the next few years. He told CNBC recently he sees more than $1 billion in gene therapy sales worldwide, which ultimately means significant investments in gene therapy in the near future.

"In the past, most major companies stayed away from having gene therapy programs. In the future, we think, it's going to be a standard treatment," he said.

See the original post:
Biotech's next buzz: Gene therapy?

MultiVir, a biotech developing gene therapies for cancer, filed on Monday with the SEC to raise up to $70 million in an initial public offering.

The Houston, TX-based company, which was founded in 2009, plans to list on the NASDAQ under the symbol MVIR. MultiVir initially filed confidentially on December 22, 2014. RBC Capital Markets is the sole bookrunner on the deal. No pricing terms were disclosed.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.

Continue reading here:
Cancer gene therapy biotech MultiVir files for a $70 million IPO

1. Introduction

Neuromuscular disease is a very broad term that encompasses many diseases and aliments that either directly, via intrinsic muscle pathology, or indirectly, via nerve pathology, impair the functioning of the muscles. Neuromuscular diseases affect the muscles and/or their nervous control and lead to problems with movement. Many are genetic; sometimes, an immune system disorder can cause them. As they have no cure, the aim of clinical treatment is to improve symptoms, increase mobility and lengthen life. Some of them affect the anterior horn cell, and are classified as acquired (e.g. poliomyelitis) and hereditary (e.g. spinal muscular atrophy) diseases. SMA is a genetic disease that attacks nerve cells, called motor neurons, in the spinal cord. As a consequence of the lost of the neurons, muscles weakness becomes to be evident, affecting walking, crawling, breathing, swallowing and head and neck control. Neuropathies affect the peripheral nerve and are divided into demyelinating (e.g. leucodystrophies) and axonal (e.g. porphyria) diseases. Charcot-Marie-Tooth (CMT) is the most frequent hereditary form among the neuropathies and its characterized by a wide range of symptoms so that CMT-1a is classified as demyelinating and CMT-2 as axonal (Marchesi & Pareyson, 2010). Defects in neuromuscular junctions cause infantile and non-infantile Botulism and Myasthenia Gravis (MG). MG is a antibody-mediated autoimmune disorder of the neuromuscular junction (NMJ) (Drachman, 1994; Meriggioli & Sanders, 2009). In most cases, it is caused by pathogenic autoantibodies directed towards the skeletal muscle acetylcholine receptor (AChR) (Patrick & Lindstrom, 1973) while in others, non-AChR components of the postsynaptic muscle endplate, such as the muscle-specific receptor tyrosine kinase (MUSK), might serve as targets for the autoimmune attack (Hoch et al., 2001). Although the precise origin of the autoimmune response in MG is not known, genetic predisposition and abnormalities of the thymus gland such as hyperplasia and neoplasia could have an important role in the onset of the disease (Berrih et al., 1984; Roxanis et al., 2001).

Several diseases affect muscles: they are classified as acquired (e.g. dermatomyositis and polymyositis) and hereditary (e.g. myotonic disorders and myopaties) forms. Among the myopaties, muscular dystrophies are characterized by the primary wasting of skeletal muscle, caused by mutations in the proteins that form the link between the cytoskeleton and the basal lamina (Cossu & Sampaolesi, 2007). Mutations in the dystrophin gene cause severe form of hereditary muscular diseases; the most common are Duchenne Muscular Dystrophy (DMD) and Becker Muscular Dystrophy (BMD). DMD patients suffer for complete lack of dystrophin that causes progressive degeneration, muscle wasting and death into the second/third decade of life. Beside, BMD patients show a very mild phenotype, often asymptomatic primarily due to the expression of shorter dystrophin mRNA transcripts that maintain the coding reading frame. DMD patients muscles show absence of dystrophin and presence of endomysial fibrosis, small fibers rounded and muscle fiber degeneration/regeneration. Untreated, boys with DMD become progressively weak during their childhood and stop ambulation at a mean age of 9 years, later with corticosteroid treatment (12/13 yrs). Proximal weakness affects symmetrically the lower (such as quadriceps and gluteus) before the upper extremities, with progression to the point of wheelchair dependence. Eventually distal lower and then upper limb weakness occurs. Weakness of neck flexors is often present at the beginning, and most patients with DMD have never been able to jump. Wrist and hand muscles are involved later, allowing the patients to keep their autonomy in transfers using a joystick to guide their wheelchair. Musculoskeletal contractures (ankle, knees and hips) and learning difficulties can complicate the clinical expression of the disease. Besides this weakness distribution in the same patient, a deep variability among patients does exist. They could express a mild phenotype, between Becker and Duchenne dystrophy, or a really severe form, with the loss of deambulation at 7-8 years. Confinement to a wheelchair is followed by the development of scoliosis, respiratory failure and cardiomyopathy. In 90% of people death is directly related to chronic respiratory insufficiency (Rideau et al., 1983). The identification and characterization of dystrophin gene led to the development of potential treatments for this disorder (Bertoni, 2008). Even if only corticosteroids were proven to be effective on DMD patient (Hyser and Mendell, 1988), different therapeutic approaches were attempted, as described in detail below (see section 7).

The identification and characterization of the genes whose mutations caused the most common neuromuscular diseases led to the development of potential treatments for those disorders. Gene therapy for neuromuscular disorders embraced several concepts, including replacing and repairing a defective gene or modifying or enhancing cellular performance, using gene that is not directly related to the underlying defect (Shavlakadze et al., 2004). As an example, the finding that DMD pathology was caused by mutations in the dystrophin gene allowed the rising of different therapeutic approaches including growth-modulating agents that increase muscle regeneration and delay muscle fibrosis (Tinsley et al., 1998), powerful antisense oligonucleotides with exon-skipping capacity (Mc Clorey et al., 2006), anti-inflammatory or second-messenger signal-modulating agents that affect immune responses (Biggar et al., 2006), agents designed to suppress stop codon mutations (Hamed, 2006). Viral and non-viral vectors were used to deliver the full-length - or restricted versions - of the dystrophin gene into stem cells; alternatively, specific antisense oligonucleotides were designed to mask the putative splicing sites of exons in the mutated region of the primary RNA transcript whose removal would re-establish a correct reading frame. In parallel, the biology of stem cells and their role in regeneration were the subject of intensive and extensive research in many laboratories around the world because of the promise of stem cells as therapeutic agents to regenerate tissues damaged by disease or injury (Fuchs and Segre, 2000; Weissman, 2000). This research constituted a significant part of the rapidly developing field of regenerative biology and medicine, and the combination of gene and cell therapy arose as one of the most suitable possibility to treat degenerative disorders. Several works were published in which stem cell were genetically modified by ex vivo introduction of corrective genes and then transplanted in donor dystrophic animal models.

Stem cells received much attention because of their potential use in cell-based therapies for human disease such as leukaemia (Owonikoko et al., 2007), Parkinsons disease (Singh et al., 2007), and neuromuscular disorders (Endo, 2007; Nowak and Davies, 2004). The main advantage of stem cells rather than the other cells of the body is that they can replenish their numbers for long periods through cell division and, they can produce a progeny that can differentiate into multiple cell lineages with specific functions (Bertoni, 2008). The candidate stem cell had to be easy to extract, maintaining the capacity of myogenic conversion when transplanted into the host muscle and also the survival and the subsequent migration from the site of injection to the compromise muscles of the body (Price et al., 2007). With the advent of more sensitive markers, stem cell populations suitable for clinical experiments were found to derive from multiple region of the body at various stage of development. Numerous studies showed that the regenerative capacity of stem cells resided in the environmental microniche and its regulation. This way, it could be important to better elucidate the molecular composition cytokines, growth factors, cell adhesion molecules and extracellular matrix molecules - and interactions of the different microniches that regulate stem cell development (Stocum, 2001).

Several groups published different works concerning adult stem cells such as muscle-derived stem cells (Qu-Petersen et al., 2002), mesoangioblasts (Cossu and Bianco, 2003), blood- (Gavina et al., 2006) and muscle (Benchaouir et al., 2007)-derived CD133+ stem cells. Although some of them are able to migrate through the vasculature (Benchaouir et al., 2007; Galvez et al., 2006; Gavina et al., 2006) and efforts were done to increase their migratory ability (Lafreniere et al., 2006; Torrente et al., 2003a), poor results were obtained.

Embryonic and adult stem cells differ significantly in regard to their differentiation potential and in vitro expansion capability. While adult stem cells constitute a reservoir for tissue regeneration throughout the adult life, they are tissue-specific and possess limited capacity to be expanded ex vivo. Embryonic Stem (ES) cells are derived from the inner cell mass of blastocyst embryos and, by definition, are capable of unlimited in vitro self-renewal and have the ability to differentiate into any cell type of the body (Darabi et al., 2008b). ES cells, together with recently identified iPS cells, are now broadly and extensively studied for their applications in clinical studies.

Embryonic stem cells are pluripotent cells derived from the early embryo that are characterized by the ability to proliferate over prolonged periods of culture remaining undifferentiated and maintaining a stable karyotype (Amit and Itskovitz-Eldor, 2002; Carpenter et al., 2003; Hoffman and Carpenter, 2005). They are capable of differentiating into cells present in all 3 embryonic germ layers, namely ectoderm, mesoderm, and endoderm, and are characterized by self-renewal, immortality, and pluripotency (Strulovici et al., 2007).

hESCs are derived by microsurgical removal of cells from the inner cell mass of a blastocyst stage embryo (Fig. 1). The ES cells can be also obtained from single blastomeres. This technique creates ES cells from a single blastomere directly removed from the embryo bypassing the ethical issue of embryo destruction (Klimanskaya et al., 2006). Although maintaining the viability of the embryo, it has to be determined whether embryonic stem cell lines derived from a single blastomere that does not compromise the embryo can be considered for clinical studies. Cell Nuclear Transfer (SCNT): Nuclear transfer, also referred to as nuclear cloning, denotes the introduction of a nucleus from an adult donor cell into an enucleated oocyte to generate a cloned embryo (Wilmut et al., 2002).

ESCs differentiation. Differentiation potentiality of human embryonic stem cell lines. Human embryonic stem cell pluripotency is evaluated by the ability of the cells to differentiate into different cell types.

Read more:
Stem Cell Therapy for Neuromuscular Diseases | InTechOpen

Pompano Beach, Florida (PRWEB) March 30, 2015

The top stem cell therapy practice in South Florida, Center of Regenerative Orthopedics, is now offering procedures to help patients avoid the need for hip and knee replacement. The procedures are partially covered by insurance and are offered by a highly skilled, Board Certified Orthopedic doctor in an outpatient setting. Call (954) 399-6945 for more information and scheduling.

Stem cell procedures for joint arthritis and pain are now mainstream and represent a cutting edge option for patients. Most nonoperative joint treatments do not actually alter the course of the disease, rather, simply act as a proverbial bandaid for relief. Stem cells, on the other hand, have the capacity to actually repair and regenerate damaged tissue such as cartilage, tendon and ligament.

Degenerative and rheumatoid arthritis affects tens of millions of Americans. Stem cell procedures have been showing excellent results for pain relief and functional improvements in small studies. By having the procedures partially covered by insurance, it makes them convenient for the general public to obtain the cutting edge option.

Joint replacement should be considered a last resort option for treatment. While typically successful, there are potential complications and they are not meant to last forever. In addition, there is minimal downtime after the stem cell procedures. Joint replacements take months to recover from afterwards.

Center of Regenerative Orthopedics is located in Pompano Beach, and sees patients throughout South Florida as well as from all over the United States. Call (954) 399-6945 to schedule with the top stem cell clinic in South Florida.

Read more:
Center of Regenerative Orthopedics in South Florida Now Offering Stem Cell Therapy to Help Avoid Hip and Knee ...

Phoenix, Arizona (PRWEB) March 30, 2015

Arizona Pain Specialists, are now offering stem cell therapy to help patients avoid hip and knee replacement. The outpatient treatments at Arizona Pain Stem Cell Institute have been exceptionally effective and are administered by Board Certified pain doctors at ten locations Valleywide. Call (602) 507-6550 for more information and scheduling.

Over the past few years, stem cell therapy for hip and knee arthritis has become mainstream. The treatment involves either bone marrow derived or amniotic derived stem cells, neither of which involve fetal tissue. The previous ethical concerns over fetal tissue and embryonic stem cells are not an issue with these treatments, as neither are involved.

The stem cell procedures are outpatient and exceptionally low risk. The stem cells, growth factors, and additional proteins in the treatments are essential for the regeneration and repair of damaged soft tissues such as tendons, ligaments and arthritic cartilage.

Although hip and knee replacement have shown exceptionally good resuts, they are not risk free procedures. They are also not meant to last forever and should be avoided until absolutely necessary.

The procedures are available throughout the Valley with Arizona Pain Specialists highly skilled, Board Certified pain management doctors in Phoenix, Scottsdale, Mesa, East Valley and West Valley. Simply call (602) 507-6550. Research studies are available as well.

See original here:
Arizona Pain Stem Cell Institute Now Offering Stem Cell Therapy to Help Patients Avoid Hip and Knee Replacement

Muscle changes following cycling and/or electrical stimulation in pediatric spinal cord injury.
Johnston TE, Modlesky CM, Betz RR, Lauer RT. Muscle changes following cycling and/or electrical stimulation in pediatric spinal cord injury. Arch Phys Med Rehabil. 2011;92(12):1937-43. 1....

By: Daryl Lawson

See more here:
Muscle changes following cycling and/or electrical stimulation in pediatric spinal cord injury. - Video

Vibrant Spinal cord injury-John
This video is about John.

By: Neurovative Technologies Inc.

Read more:
Vibrant Spinal cord injury-John - Video

The amazing Dr. John Apsley, expert in Regenerative Medicine!
Dr. John Apsley offers an very informative session on the construction of water, its vital qualities and the need to eat foods that are organic and mineral rich.

By: I AM NATURE

Continue reading here:
The amazing Dr. John Apsley, expert in Regenerative Medicine! - Video

What is Regenerative medicine in orthopedics
Siddharth Tambar MD, the physician at Chicago Arthritis, discusses regenerative medicine in orthopedics.

By: Chicago Arthritis

Original post:
What is Regenerative medicine in orthopedics - Video

Stem cell research has long been seen as a new frontier for disease therapeutics. By coaxing stem cells to form 3D miniature lung structures, University researchers are helping explain why.

In a collaborative study, University researchers devised a system to generate self-organizing human lung organoids, or artificially-grown organisms. These organoids are 3D models that can be used to better understand lung diseases.

Jason Spence, the assistant professor of internal medicine and cell and developmental biology, who was a senior author of the study, said one of the key implications of these lungs is the controlled environment they offer for future research.

These mini lungs will allow us to study diseases in a controlled environment and to develop and test new drugs, he said.

Specifically, Spence said, scientists will be able to take skin samples from patients with a particular form of a lung disease, reprogram the cells into stem cells and then generate lung tissue for further study. He said by analyzing the disease in a controlled environment, researchers can gain insight into the progression of various diseases and then tailor drugs for treatment.

Rackham student Briana Dye was also a lead author of the study. She said the team manipulated numerous signaling pathways involved with cell growth and organ formation to make the miniature lungs.

First, Dye said the scientists used proteins called growth factors to differentiate embryonic stem cells into endoderm, the germ layer that gives rise to the lungs. Different growth factors were then used to cause the endoderm to become lung tissue.

We add specific growth factors, proteins that turn on pathways in the cells, that will then cause them to lift off the monolayer so that we have this 3D spherical tissue, she said.

Previous research has used stem cells in a similar manner to generate brain, intestine, stomach and liver tissue. Dye said one of the advantages of stem cell research is its direct path to studying human tissue.

We have worked with many animal models in the past, Dye said. Animal models present obstacles because they dont exactly behave the way human tissue and cells do. This is why stem cells are so promising.

Read more here:
Research develops mini-lung structures

Genetics 4 Meiosis

By: Matthew Moorman

Read the original:
Genetics 4 Meiosis - Video

Lets Play The Sims 3 100 Baby/ Perfect Genetics CAS SPECIAL
DONATIONS (Optional): ...

By: GBabyChallenger

Go here to see the original:
Lets Play The Sims 3 100 Baby/ Perfect Genetics CAS SPECIAL - Video

The ACMG Foundation for Genetic and Genomic Medicine announces the first recipient of the ACMG Foundation Carolyn Mills Lovell Award at the 2015 ACMG Annual Clinical Genetics Meeting in Salt Lake City, Utah: First award specifically for genetic counselors

Stephanie Harris, CGC was honored as the first recipient of the ACMG Foundation Carolyn Mills Lovell Award at the American College of Medical Genetics and Genomics (ACMG) 2015 Annual Clinical Genetics Meeting in Salt Lake City, Utah.

Ms. Harris was selected to receive the award for her poster presentation, "The Impact of Variant Reclassification on Hypertrophic Cardiomyopathy Research".

Ms. Harris completed her Masters of Science in Human Genetics and Genetic Counseling at Stanford University School of Medicine in Stanford, CA. and her Bachelor of Science in Biology at Bucknell University in Lewisburg, PA. She is currently a genetic counselor in Cardiovascular Genetics at Brigham and Women's Hospital in Boston, MA.

This award was made possible due to a generous donation by ACMG Medical Director David Flannery, MD, FAAP, FACMG to honor genetic counselor Carolyn Mills Lovell, MAT, MS, CGC. Dr. Flannery worked with Ms. Lovell for over 15 years while he was at the Medical College of Georgia (MCG) of Georgia Regents University, and wanted to recognize the contributions and accomplishments of genetic counselors through this award. This award includes a cash prize of $1000 and will be presented to one recipient annually through 2025.

"I wanted to help recognize genetic counselors who play a huge role in clinical genetic services and felt that this award would help with that and also honor Carolyn, who has always provided exemplary services to families, students and residents at MCG " said ACMG Medical Director David Flannery, MD, FAAP, FACMG.

ACMG Foundation President Bruce R. Korf, MD, PhD, FACMG added, "It is exciting to see the ACMG Foundation offer an award intended specifically for genetic counselors. Genetic counselors are integral members of the genetics care team and their role is expanding in this era of genomic medicine. I am very pleased to see the contribution of genetic counselors recognized through this award."

###

The ACMG Foundation for Genetic and Genomic Medicine, a 501(c)(3) nonprofit organization, is a community of supporters and contributors who understand the importance of medical genetics in healthcare. Established in 1992, the ACMG Foundation for Genetic and Genomic Medicine supports the American College of Medical Genetics and Genomics; mission to "translate genes into health" by raising funds to attract the next generation of medical geneticists and genetic counselors, to sponsor important research, to promote information about medical genetics, and much more.

To learn more about the important mission and projects of the ACMG Foundation for Genetic and Genomic Medicine and how you too can support this great cause, please visit http://www.acmgfoundation.org or contact us at acmgf@acmgfoundation.org or 301/718-2014.

View original post here:
ACMG Foundation announces inaugural recipient of Lovell Award

Gentech Lesson: Gene Therapy
Momes Honors Bio EB/1: Gentech Lesson on Gene Therapy. By Sarah, Jordan, Lisa, Sydney.

By: Sarah Minster

Go here to see the original:
Gentech Lesson: Gene Therapy - Video

Colorblind monkey cured by gene therapy...
Dalton, a squirrel monkey, is cured of colorblindness by gene therapy and completes color vision discrimination test. Dalton, a squirrel monkey, is cured of colorblindness by gene therapy and...

By: LisaMarintMEw

Continued here:
Colorblind monkey cured by gene therapy... - Video

Ask Dr. Lemper | Stem Cell Therapy Treatments
Facebook https://www.facebook.com/lemperpaincenters Submit a question https://bit.ly/askdrlemper Continuing #39;Ask Dr Lemper #39;, Dr. Lemper answers the following question: Do you think...

By: Dr. Brian Lemper, D.O.

Read this article:
Ask Dr. Lemper | Stem Cell Therapy Treatments - Video

Orthopedic Rehabilitation Treatment using Personalized Medicine | Russ Scala
The Institute offers Orthopedic Rehabilitation treatments that are customized to each individuals biological and genetic markers. This approach speeds the treatment and recovery process with...

By: Russ Scala

See the original post here:
Orthopedic Rehabilitation Treatment using Personalized Medicine | Russ Scala - Video

Dr. Prashant Yadav speaking on the topic Personalized Medicine

By: Healthcare Executive

Link:
Dr. Prashant Yadav speaking on the topic Personalized Medicine - Video

Dr Kreutz Personalized Medicine a Case Study

By: Indiana Institute for Personalized Medicine (IIPM)

Read more:
Dr Kreutz Personalized Medicine a Case Study - Video